A retrospective cohort study of 318 patients with breast cancer with leptomeningeal metastases was conducted to describe patient characteristics and outcomes. Independent factors associated with survival after the diagnosis of leptomeningeal metastases were identified. Such information is useful in management and in clinical trial development of patients with breast cancer with leptomeningeal metastases. Background: Disease presentation, prognostic factors, and treatment patterns for patients with breast cancer with leptomeningeal metastasis are not well characterized. In this study, we examined patient characteristics and prognostic factors for survival after a diagnosis of leptomeningeal metastasis. Patients and Methods: Three hundred eighteen consecutive patients with breast cancer diagnosed with leptomeningeal metastasis from January 1998 to December 2013 at Memorial Sloan Kettering Cancer Center were identified. Clinicopathologic and treatment information were obtained in a retrospective review. Associations with time from leptomeningeal diagnosis to death were evaluated according to KaplaneMeier curves, log rank tests, and Cox proportional hazard models. Results: Of the 318 patients, 44% were hormone receptor-positive (HRþ) HER2
Introduction
Breast cancer is one of the common solid tumors to metastasize to the central nervous system (CNS). In particular, leptomeningeal metastasis (LM) is associated with significant morbidity and mortality. The incidence of LM in breast cancer is reported to be approximately 5%. 1 Additionally, we reported a 14% prevalence of concurrent LM at the time of brain metastasis diagnosis in our HER2-positive (HER2 þ ) breast cancer brain metastases cohort. 2 The survival of patients with LM is known to be very short and therapeutic options and their efficacy are often limited. 1, 3 Current treatment options for LM are local therapies such as radiotherapy and intrathecal (IT)/intraventricular therapy. However, the efficacy of IT/intraventricular therapy is not well established in patients with breast cancer and is associated with significant neurotoxicity. 4 Therefore, assessing appropriate candidates for active therapeutic intervention is an important consideration. Among breast cancer patients with CNS metastases, the HER2 þ subpopulation has a relatively better prognosis and in this group CNS-penetrating targeted therapy is under investigation. For patients with LM, disease presentation, prognostic factors, and treatment patterns are not well defined. Improvement in breast cancer treatment including HER2-targeted therapy, might have improved the outcome of patients with LM over time. We hypothesize that receptor subytpe might be an important prognostic factor for patients with LM, similar to what has been reported for patients with brain metastases. [5] [6] [7] The objectives of this retrospective study were to examine a modern cohort of patients with breast cancer diagnosed with leptomeningeal disease at Memorial Sloan Kettering Cancer Center (MSKCC), describe patient characteristics and treatment patterns, and determine factors associated with survival after LM diagnosis. The results of this study will add to our understanding of the contemporary epidemiology of LM in breast cancer and provide prognostic factors that will be useful in management of patiens with LM and in designing future clinical trials in this population.
Patients and Methods

Study Population
Consecutive patients with breast cancer diagnosed with LM from January 1998 to December 2013 and treated at MSKCC were identified from an institutional database after approval from the institutional review board. LM diagnosis was determined on the basis of magnetic resonance imaging MRI reports or positive cerebrospinal fluid (CSF) studies. Additionally, patients suspected to have LM on MRI or according to CSF cytology were included if the treating oncologist or neurologist documented the LM diagnosis and LM-directed therapy (eg, intrathecal therapy [IT]).
Data Collection
Clinicopathologic information was abstracted using a retrospective chart review and included the following variables: hormone receptor (HR; estrogen (ER), and progesterone (PR),) status, HER2 status, stage and grade of the primary tumor, age at LM diagnosis, date of initial LM diagnosis, site of LM involvement (classified as cranial only, spinal only, or both), method of LM diagnosis (cytology, imaging, or both), metastatic diagnosis (date of metastatic breast cancer diagnosis) and extent (sites of metastatic disease, eg, liver, bone, lung), and control of non-CNS disease at the time of LM diagnosis (classified either as progression, nonprogression, or no evidence of disease), history of brain metastasis diagnosis, Karnofsky performance status (KPS) score at the time of LM diagnosis, local CNS-directed therapy (radiation, surgery, and IT), and systemic therapy. KPS score was dichotomized at the cutoff of 70, and the date of initial LM diagnosis was dichotomized at 2006, a midpoint between 1998 and 2013, for further analyses.
Statistical Analysis
Clinicopathologic data were summarized using median and ranges for continuous variables and proportions for categorical variables. Overall survival was defined as the time from LM diagnosis to death or last date of follow-up. Survival estimates were calculated using the KaplaneMeier method and comparisons were made using the log rank test. In addition, hazard ratios were calculated using a Cox proportional hazards model. Multivariable Cox regression analysis was performed to identify prognostic factors for overall survival. Proportional hazard assumptions were evaluated for each variable considered in the multivariable analysis. Selection of variables for the multivariable model was on the basis of the significance of univariate findings. Variables known to be prognostic (such as age) and thus important to adjust for in the model were also included. All the statistical calculations were performed using SAS version 9.4 (SAS Institute Inc, Cary, NC) and R (https://www.rproject.org). P values < .05 were considered to be statistically significant and all tests were 2-sided.
Results
Patient Characteristics
A total of 318 patients with breast cancer with LM who met the study inclusion criteria were identified from January 1, 1998 to December 31, 2013. The patient characteristics and treatment information are shown in had CSF cytology evaluation, 34% of the cohort (100 of 318) had positive CSF cytology, and 7 of 318 had cytology suspected to indicate LM. In our cohort, the LM treatments included radiation, ventriculoperitoneal shunt placement, IT/intraventricular therapy, and systemic therapy (eg, intravenous high-dose chemotherapy).
Survival From the Time of LM Diagnosis
The median time to death for the cohort was 3. Figure 1B ). We hypothesized that with increasing use of anti-HER2 therapies and the introduction of lapatinib (a small-molecule tyrosine kinase inhibitor anti-HER2 therapy), we might observe a change in survival for HER2 þ patients over time. We dichotomized the cohort and examined the median survivals for HER2 þ patients. In an exploratory analysis, the median survival was 3.3 months (95% CI, 2.4-5.0) before the year 2005 and 7.0 months (95% CI, 3.7-12.2) thereafter. The final multivariable model included age at the time of LM diagnosis, year at the time of LM diagnosis, KPS score, receptor subtype, site of LM involvement (eg, cranial, spinal, or both), and non-CNS disease control status ( Table 2) . As expected, patients with poorer KPS scores ( 70) had a shorter survival (HR, 2.31; 95% CI, 1.64-3.24; P < .001). The year at LM diagnosis (dichotomized at year 2005) remained a significant factor in a multivariate analysis (HR, 1.40; 95% CI, 1.04-1.88; P ¼ .03).
Unlike patients with brain metastasis, for whom HER2 expression is associated with a longer survival, in our LM Interestingly, the sites of LM involvement remained a significant factor because cranial-only involvement was favorable as opposed to spinal involvement (type III P ¼ .04).
Discussion
This is the largest cohort of breast cancer patients from a single center with an LM diagnosis reported to date. 8, 9 Consistent with other reports, we have observed that patients diagnosed with LM have a short median survival after LM diagnosis; most of these succumb to the disease within a year. Importantly, 20% of our cohort (63 of 318) survived longer than a year. We therefore examined prognostic factors associated with survival after LM diagnosis. Because there is a major selection bias associated with LM therapy administration (eg, systemic and IT/intraventricular therapy), the use of LM therapy was evaluated in a descriptive manner only and was not examined as a possible prognostic factor in our model. Receptor subtype has proved to be an important prognostic factor for patients with breast cancer with parenchymal brain metastasis. 10, 11 We therefore hypothesized that receptor subtype would be a similarly important prognostic factor as observed for breast cancer patients with LM. Patients with HER2 þ status and brain metastasis have a favorable prognosis compared with other subtypes. 10, 11 However, in our cohort, survival from the time of LM diagnosis was similar for HER2 þ and HR þ HER2 À patients. Consistent with In patients with parenchymal brain metastasis, it has been theorized that the relatively favorable prognosis associated with HER2
þ CNS metastasis is due to the improvement in non-CNS disease control from the use of anti-HER2 drugs and the introduction of lapatinib, which has shown CNS uptake and activity in CNS metastasis. [13] [14] [15] [16] [17] [18] In an exploratory univariate analysis, we observed that the survival for HER2 þ patients who were diagnosed in more recent years (after 2005, coinciding with increasing use of lapatinib for HER2 þ CNS metastases at our institution) had a longer median survival compared with those who were diagnosed before 2005. However, because of the small number of patients, an interaction between the subtype and the year of LM diagnosis was not examined in our multivariate model.
No effective standard targeted therapy for LM has been introduced for routine clinical practice during the study period. 19 We therefore hypothesized that the improvement in survival over time might be attributable to improvement in systemic therapy. With advent of small-molecule drugs and drugs modified to improve CNS penetration, systemic therapy for CNS metastasis is now actively investigated in prospective clinical trials. 13 The efficacy of systemic therapy for LM might therefore be best examined through prospective clinical trials specifically targeting this population.
Intrathecal chemotherapy for patients with breast cancer remains controversial. 4 First, therapies directly administered into this space have limited penetration, so IT is generally reserved for patients with disease not evident on MRI or those with non-bulky leptomeningeal metastases. Second, a limited range of drugs are classically suitable for IT administration (methotrexate, cytarabine, and thiotepa). Attempts are under way to expand the repertoire of IT Unexpectedly, we observed that patients with cranial-only involvement of LM showed improved survival. It is unclear if this finding is due to a difference in biology or detection bias, because most but not all patients underwent brain and total spine imaging at the time of LM diagnosis. It is possible that the patients with spinal LM involvement might have had a delay in diagnosis as neurologic symptoms referable to the spine and spinal roots might have been misattributed to bone metastasis and other non-LM diagnoses. In an exploratory analysis, we examined specific sites of non-CNS metastases (eg, lung, bone, liver) as variables, but the presence of bone metastasis was not significantly associated with outcome in univariate analysis. Our observation has an important implication for considering routine and systematic imaging of cranial and spinal compartments for patients with LM. 20 It would be of interest to systematically evaluate the extent of LM involvement in a prospective manner to validate whether the site of LM involvement is an important prognostic factor. Our study has several limitations due to its retrospective nature. Reflective of current clinical practice, not all patients underwent CSF cytologic evaluation and complete imaging of the neuroaxis. However, we conducted an exploratory analysis according to the LM diagnosis method. The survival did not differ between patients who had positive CSF cytology and patients whose LM diagnosis was made using imaging findings only (without CSF evaluation). The patients who were diagnosed using imaging but with negative cytology had a significantly longer survival (P ¼ .01). Such a difference might be explained by the disease burden or possible misclassification. We did include 3 patients for whom we were unable to obtain source information on imaging or CSF cytology because those evaluations were reported from an outside institution's records, and the patients were treated clinically for LM. Receipt of systemic therapy or LM therapy was not evaluated as an independent prognostic variable because it would have been influenced by the performance status and the status and extent of non-CNS disease.
Conclusion
Most patients with LM have a limited survival, but a subset of patients with a more favorable prognosis exists for whom further active anticancer therapy might be appropriate. Receptor subtype is an important prognostic factor and should be accounted for in future studies involving breast cancer patients with LM. An improvement in outcomes for HER2 þ patients with LM parallels the emergence of highly effective anti-HER2 therapy, and suggests a potential treatment effect. Several trials are currently evaluating molecular targeted drug therapy (eg, high dose lapatinib, intrathecal trastuzumab, and abemaciclib) for breast cancer patients with LM (NCT02650752, NCT01325207, NCT02308020). Our data support the ongoing clinical trials that are examining the use of systemic drugs to improve the outcome of the LM patients.
Clinical Practice Points
There is a paucity of information regarding characteristics and prognosis of patients with breast cancer with leptomeningeal disease, especially in context of changes in therapeutic options and epidemiology of CNS metastasis in patients with breast cancer over the recent decades. Our study showed that patients with breast cancer who are more recently diagnosed with leptomeningeal metastases and HER2 þ patients had a longer survival. Despite fact that LM might be associated with a limited survival, there is a subset of patients who might benefit from continued active therapy as shown by 20% of our cohort who survived longer than 1 year. Results of this study informs ongoing efforts to study new therapeutic options for patients with leptomeningeal metastases. Patients with good prognostic features might be reasonable candidates for additional active therapies and LM-focused clinical trials.
